Definition

An orally bioavailable inhibitor of SRC family of kinases (SFK), including SRC and YES1, with potential antineoplastic activity. Upon oral administration, SRC/YES1 kinase inhibitor NXP900 targets, binds to, and locks SRC and YES1 into their native closed conformation, thereby inhibiting both their kinase activity and their association with protein signaling partners. This inhibits the oncogenic signaling pathways mediated by these kinases and the proliferation of tumor cells overexpressing these kinases. SRC family of kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis.